SwePub
Sök i LIBRIS databas

  Extended search

onr:"swepub:oai:DiVA.org:uu-470108"
 

Search: onr:"swepub:oai:DiVA.org:uu-470108" > Timing of allogenei...

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist
  • Hu, Bei (author)

Timing of allogeneic hematopoietic cell transplantation (alloHCT) for chronic myeloid leukemia (CML) patients

  • Article/chapterEnglish2020

Publisher, publication year, extent ...

  • 2020-07-14
  • Informa UK Limited,2020
  • printrdacarrier

Numbers

  • LIBRIS-ID:oai:DiVA.org:uu-470108
  • https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-470108URI
  • https://doi.org/10.1080/10428194.2020.1783444DOI
  • http://kipublications.ki.se/Default.aspx?queryparsed=id:144198286URI

Supplementary language notes

  • Language:English
  • Summary in:English

Part of subdatabase

Classification

  • Subject category:ref swepub-contenttype
  • Subject category:art swepub-publicationtype

Notes

  • While TKI are the preferred first-line treatment for chronic phase (CP) CML, alloHCT remains an important consideration. The aim is to estimate residual life expectancy (RLE) for patients initially diagnosed with CP CML based on timing of alloHCT or continuation of TKI in various settings: CP1 CML, CP2 + [after transformation to accelerated phase (AP) or blast phase (BP)], AP, or BP. Non-transplant cohort included single-institution patients initiating TKI and switched TKI due to failure. CIBMTR transplant cohort included CML patients who underwent HLA sibling matched (MRD) or unrelated donor (MUD) alloHCT. AlloHCT appeared to shorten survival in CP1 CML with overall mortality hazard ratio (HR) for alloHCT of 2.4 (95% CI 1.2-4.9;p = .02). In BP CML, there was a trend toward higher survival with alloHCT; HR = 0.7 (0.5-1.1;p = .099). AlloHCT in CP2 + [HR = 2.0 (0.8-4.9),p = .13] and AP [HR = 1.1 (0.6-2.1);p = .80] is less clear and should be determined on a case-by-case basis.

Subject headings and genre

Added entries (persons, corporate bodies, meetings, titles ...)

  • Lin, Xiao (author)
  • Lee, Hans C. (author)
  • Huang, Xuelin (author)
  • Tidwell, Rebecca S. Slack (author)
  • Ahn, Kwang Woo (author)
  • Hu, Zhen-Huan (author)
  • Jabbour, Elias (author)
  • Verstovsek, Srdan (author)
  • Ravandi, Farhad (author)
  • Garcia-Manero, Guillermo (author)
  • Kharfan-Dabaja, Mohamed A. (author)
  • Hossain, Nasheed M. (author)
  • Marks, David I. (author)
  • Kamble, Rammuriti T. (author)
  • Inamoto, Yoshihiro (author)
  • Kindwall-Keller, Tamila (author)
  • Saad, Ayman (author)
  • Litzow, Mark R. (author)
  • Savani, Bipin N. (author)
  • Hale, Gregory A. (author)
  • Bacher, Ulrike (author)
  • Gerds, Aaron T. (author)
  • Liesveld, Jane L. (author)
  • Ustun, Celalettin (author)
  • Olsson, RichardUppsala universitet,Centrum för klinisk forskning i Sörmland (CKFD)(Swepub:uu)riols677 (author)
  • Daly, Andrew (author)
  • Grunwald, Michael R. (author)
  • Solh, Melhem (author)
  • DeFilipp, Zachariah (author)
  • Aljurf, Mahmoud (author)
  • Wirk, Baldeep (author)
  • Akpek, Gorgun (author)
  • Nishihori, Taiga (author)
  • Cerny, Jan (author)
  • Seo, Sachiko (author)
  • Hsu, Jack W. (author)
  • Champlin, Richard (author)
  • de Lima, Marcos (author)
  • Alyea, Edwin (author)
  • Popat, Uday (author)
  • Sobecks, Ronald (author)
  • Scott, Bart L. (author)
  • Kantarjian, Hagop (author)
  • Cortes, Jorge (author)
  • Saber, Wael (author)
  • Uppsala universitetCentrum för klinisk forskning i Sörmland (CKFD) (creator_code:org_t)

Related titles

  • In:Leukemia and Lymphoma: Informa UK Limited61:12, s. 2811-28201042-81941029-2403

Internet link

Find in a library

To the university's database

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view